Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17766691 | 1.00 | LMNA (0.32) | LMNATDP1CA12CA1CA2 | |
| SCHEMBL4746164 | 1.00 | LMNA (0.32) | LMNATDP1CA12CA1CA2 | |
| SCHEMBL17766693 | 1.00 | LMNA (0.32) | LMNATDP1CA12CA1CA2 | |
| SCHEMBL4745076 | 1.00 | LMNA (0.32) | LMNATDP1CA12CA1CA2 | |
| SCHEMBL16781965 | 0.91 | — | — | |
| SCHEMBL272858 | 0.89 | TDP1 (0.36) | LMNATDP1KDM4E | |
| SCHEMBL18551186 | 0.88 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL20733072 | 0.88 | CYP2C19 (0.48) | TP53 | |
| SCHEMBL19836838 | 0.88 | — | — | |
| SCHEMBL14952396 | 0.88 | ALDH1A1 (0.35) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1914254-B1 | Crosslinkers for improving stability of polyurethane foams | EVONIK DEGUSSA GMBH (DE) | 2017-08-23 | — | — | EP | claimed |
| EP-1914254-A1 | Crosslinkers for improving stability of polyurethane foams | Air Products and Chemicals, Inc. (US) | 2008-04-23 | — | — | EP | claimed |
| US-20080090922-A1 | Crosslinkers for improving stability of polyurethane foams | EVONIK OPERATIONS GMBH (DE) | 2008-04-17 | — | — | US | claimed |
| WO-2025062883-A1 | SYSTEM FOR REMOVING NITROGEN OXIDES AND/OR SULFUR OXIDES, METHOD FOR REMOVING NITROGEN OXIDES AND/OR SULFUR OXIDES, SYSTEM FOR SEPARATING AND CAPTURING CARBON DIOXIDE, AND METHOD FOR SEPARATING AND CAPTURING CARBON DIOXIDE | 国立大学法人京都工芸繊維大学 | 2025-03-27 | — | — | WO | disclosed |
| WO-2023182173-A1 | CARBON DIOXIDE ISOLATOR, METHOD FOR ISOLATING OR RECOVERING CARBON DIOXIDE, AND METHOD FOR PRODUCING CARBON DIOXIDE ISOLATOR | 公益財団法人地球環境産業技術研究機構 | 2023-09-28 | — | — | WO | disclosed |
| US-11584933-B2 | RNA interference in ocular indications | PHIO PHARMACEUTICALS CORP. (US) | 2023-02-21 | — | — | US | disclosed |
| EP-3390483-B1 | ENCAPSULATION | PROCTER & GAMBLE (US) | 2022-05-18 | — | — | EP | disclosed |
| EP-3368207-B1 | ENCAPSULATION | ENCAPSYS LLC (US) | 2021-12-01 | — | — | EP | disclosed |
| US-11001845-B2 | Nucleic acid molecules targeting superoxide dismutase 1 (SOD1) | PHIO PHARMACEUTICALS CORP. (US) | 2021-05-11 | — | — | US | disclosed |
| US-20210062195-A1 | RNA INTERFERENCE IN OCULAR INDICATIONS | PHIO PHARMACEUTICALS CORP. (US) | 2021-03-04 | — | — | US | disclosed |
| US-10864167-B2 | Encapsulation | THE PROCTER & GAMBLE COMPANY (US) | 2020-12-15 | — | — | US | disclosed |
| US-20170067056-A1 | RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS | RXI PHARMACEUTICALS CORPORATION (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170051290-A1 | METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES | RXI PHARMACEUTICALS CORPORATION (US) | 2017-02-23 | — | — | US | disclosed |
| US-20160144340-A1 | CARBON DIOXIDE SEPARATING MATERIAL, AND METHOD FOR SEPARATION OR RECOVERY OF CARBON DIOXIDE | RESEARCH INSTITUTE OF INNOVATIVE TECHNOLOGY FOR THE EARTH (JP) | 2016-05-26 | — | — | US | disclosed |
| US-8552078-B2 | Non-fugitive tertiary amine catalyst and alkylated polyamine crosslinking additives; aging resistance | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20110052673-A1 | THERAPEUTIC COMPOSITIONS | SHIRE HUMAN GENETIC THERAPIES, INC. | 2011-03-03 | — | — | US | disclosed |
| US-20110009641-A1 | Amine-containing lipids and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-01-13 | — | — | US | disclosed |
| WO-2008112636-A1 | CHAIN EXTENDERS | ALBEMARLE CORPORATION (US) | 2008-09-18 | — | — | WO | disclosed |
| EP-1914254-A1 | Crosslinkers for improving stability of polyurethane foams | Air Products and Chemicals, Inc. (US) | 2008-04-23 | — | — | EP | disclosed |
| US-20080090922-A1 | Crosslinkers for improving stability of polyurethane foams | EVONIK OPERATIONS GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584933-B2 | RNA interference in ocular indications | RXRA, RXRB, RXRG | LMNA 1015/4885TDP1 3077/4885CA12 4498/4885 |
| US-20110052673-A1 | THERAPEUTIC COMPOSITIONS | PHOSPHO1, SGMS1, APOB | LMNA 536/4885TDP1 3041/4885CA12 1652/4885 |
| US-11001845-B2 | Nucleic acid molecules targeting superoxide dismutase 1 (SOD1) | SOD1, SOD3, POLRMT | LMNA 583/4885TDP1 57/4885CA12 3945/4885 |
| US-20170051290-A1 | METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES | POLRMT, NSUN3, ELAVL1 | LMNA 461/4885TDP1 496/4885CA12 1935/4885 |
| US-20110009641-A1 | Amine-containing lipids and uses thereof | PHOSPHO1, CHMP4B, SGMS1 | LMNA 402/4885TDP1 1468/4885CA12 4058/4885 |
| US-10864167-B2 | Encapsulation | ACR, MPHOSPH6, ACMSD | LMNA 1251/4885TDP1 653/4885CA12 3364/4885 |
| US-20210062195-A1 | RNA INTERFERENCE IN OCULAR INDICATIONS | RXRA, RXRB, RXRG | LMNA 1015/4885TDP1 3077/4885CA12 4498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.